Dapagliflozin benefits heart failure patients regardless of their gout status: JAMA Medha Baranwal27 Feb 2023 10:30 AM ISTUK: A post hoc analysis of 2 trials revealed that dapagliflozin's benefit is consistent in heart failure (HF) patients irrespective of gout. The use...
Sun Pharma Gets CDSCO panel nod to manufacture, market antidiabetic FDC drug Dr. Divya Colin24 Feb 2023 6:00 PM ISTNew Delhi: In a significant development, pharmaceutical major, Sun Pharma has got the go-ahead from the Subject Expert Committee (SEC) functional...
AstraZeneca Forxiga approved in EU for treatment of symptomatic chronic heart failure Ruchika Sharma7 Feb 2023 4:15 PM ISTForxiga (dapagliflozin) is a first-in-class, oral, once-daily SGLT2 inhibitor.
Dapagliflozin reduces hospitalization risk in CKD patients regardless of diabetes status Medha Baranwal22 Dec 2022 7:15 AM ISTIsrael: SGLT2 inhibitor dapagliflozin may reduce the hospitalization risk due to any cause in patients with CKD (chronic kidney disease) irrespective...
AstraZeneca Forxiga recommended for nod in EU for chronic heart failure Ruchika Sharma20 Dec 2022 5:30 PM ISTHeart failue is a life-threatening chronic disease in which the heart cannot pump enough blood around the body, affecting 15 million people in the EU.
CDSCO nod to AstraZeneca Pharma Dapagliflozin tablets Ruchika Sharma28 Nov 2022 4:30 PM ISTThe receipt of this permission paves way for the launch of Dapagliflozin (Forxiga) tablets of 10 mg in India for the specified additional/expanded...
Dapagliflozin benefits Heart failure patients Independent of baseline kidney function: JAMA Dr. Kamal Kant Kohli16 Nov 2022 10:45 AM ISTMassachusetts: According to research published in JAMA Cardiology, baseline renal function did not alter the benefit of dapagliflozin in individuals...
Dapagliflozin effective from clinical standpoint as well as cost standpoint for CKD patients Dr. Kamal Kant Kohli5 Nov 2022 9:30 AM ISTThe burden of chronic kidney disease (CKD) to both healthcare systems and patients is considerable. Dapagliflozin, a sodium-glucose cotransporter-2...
Medical Bulletin 3/November/2022 Isra Zaman3 Nov 2022 11:26 AM ISTHere are the top medical news for the day:ACC, AHA guideline on the diagnosis and management of aortic diseaseThe aorta is the largest artery in the...
Dapagliflozin clinically and cost effective in patients with chronic kidney disease: DAPA-CKD trial Isra Zaman3 Nov 2022 9:15 AM IST A recent analysis in CJASN indicates that in patients eligible for the DAPA-CKD trial, dapagliflozin is not only effective from a clinical...
Do SGLT2 inhibitors lower blood sugar by increasing insulin sensitivity in diabetes patients? Dr Kartikeya Kohli29 Oct 2022 8:15 PM ISTIran: With development of various novel medications, particularly sodium-glucose cotransporter 2 inhibitors (SGLT2Is), medical men are one step closer...
AstraZeneca Gets CDSCO panel nod to Import, Market Anti-Diabetic Dapagliflozin for Additional Indication Dr. Divya Colin23 Oct 2022 11:30 AM ISTNew Delhi: Pharmaceutical major AstraZeneca has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drugs Standard...
